AI Governance as an Extension of Computer System Validation
No FDA or EMA document currently establishes a distinct regulatory category for AI validation. FDA's discussion papers on AI/ML in drug development and its January 2025 draft guidance on AI supporting regulatory decision-making, along with EMA's 2023 Reflection Paper on AI in the medicinal product lifecycle, each frame AI oversight as an extension of existing computer system validation and data integrity principles rather than a new regime. The operative binding requirements remain 21 CFR Part 11, EU GMP Annex 11, GAMP 5, and PIC/S data integrity guidance (PI 041).
For AI governance leaders, this means AI-enabled components in manufacturing, quality, clinical, and lab systems should be validated using the same risk-based logic FDA's Computer Software Assurance (CSA) guidance applies to conventional software, categorized under GAMP 5's existing risk framework, and documented with the same rigor Part 11 and Annex 11 require for any GxP computerized system. The practical challenge is interpretation: these frameworks were not written with autonomous, tool-calling AI agents in mind, and organizations must document how existing controls apply to agent-based architectures rather than waiting for AI-specific regulation to be finalized.
Why Agentic AI Creates an Audit Trail Gap
Part 11 requires secure, computer-generated, time-stamped audit trails that independently record operator actions creating, modifying, or deleting electronic records. Annex 11 imposes a parallel requirement for GMP-relevant changes to data. Both were drafted for systems where a human operator initiates a discrete, loggable action. AI agents that autonomously select tools, chain multiple calls, and make intermediate decisions before producing a final output do not map cleanly onto that model.
A single agent task may involve several tool invocations, none of which resembles a traditional operator edit, yet each may be GxP-relevant if it touches manufacturing, quality, or clinical data. Closing this gap requires audit logs that capture not just the final output but the sequence of inputs, decisions, and tool calls that produced it, recorded independently of the agent itself so the record cannot be altered by the same process it documents. This is consistent with ALCOA+ principles under PIC/S guidance, which require data to be attributable, contemporaneous, and enduring regardless of whether a human or an AI agent generated it.
Audit evidence for AI agents should be attributable and independent of the agent process: log inputs, intermediate decisions, and tool invocations, not only the final output.
Mapping AI Validation Into Existing Quality Systems
The questions below address how CSA, revalidation triggers, and runtime controls fit into existing GxP quality systems when AI agents are in scope.
Does CSA replace CSV for validating AI components?
No. CSA is a risk-based assurance approach FDA has promoted since 2022 for production and quality system software generally. It reduces reliance on exhaustive scripted testing but does not eliminate validation obligations, and it applies to AI components the same way it applies to conventional software.
What triggers revalidation of an AI agent in a GxP system?
Regulatory papers point to model updates, configuration changes, and detected behavior drift as events warranting revalidation, consistent with CSA's risk-based logic. Organizations should define these triggers explicitly rather than relying on fixed revalidation schedules.
How is runtime policy enforcement different from validation documentation?
Validation documentation demonstrates that a system was assessed and controlled before and during deployment. Runtime policy enforcement, such as scoped tool permissions and monitored agent actions, provides the ongoing technical control layer that generates the evidence validation documentation depends on.